DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. As of September 11, 2025, DURECT Corporation operates as a subsidiary of Bausch Health Americas, Inc.
Часто задаваемые вопросы
В каком секторе работает Durect Corporation (DRRX)?
Durect Corporation относится к сектору Здравоохранение.
Какова текущая цена акций Durect Corporation (DRRX)?
По последним данным, цена акций Durect Corporation составляет 1,91 $, предыдущее закрытие — 1,91 $.
Выплачивает ли Durect Corporation (DRRX) дивиденды?
Нет, Durect Corporation не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Durect Corporation (DRRX)?
У компании Durect Corporation бета 0.928, что означает, что её волатильность примерно соответствует рыночной.
